Novavax Announces Leadership Change
October 13 2017 - 7:30AM
YASTEST
GAITHERSBURG, Md., Oct. 13, 2017
(GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) announced today
that Barclay A. "Buck" Phillips has submitted his resignation as
Senior Vice President, Chief Financial Officer (CFO) and Treasurer,
to pursue an expanded opportunity in the industry. Mr. Phillips
will step down effective November 10, 2017, and will provide
financial, accounting and transition services as a consultant to
Novavax until December 31, 2017. Mr. Erck will act as the interim
CFO pending completion of a search for a new Chief Financial
Officer.
"Buck has been instrumental in a
number of significant Novavax accomplishments, and we thank him for
all his contributions over the last four years. We wish him all the
best in his new endeavors," said Stanley C. Erck, President and CEO
of Novavax.
About
Novavax
Novavax, Inc. (Nasdaq:NVAX) is a
clinical-stage biotechnology company committed to delivering novel
products to prevent a broad range of infectious diseases. Our
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are
the foundation for groundbreaking innovation that improves global
health through safe and effective vaccines. Additional information
about Novavax is available on the Company's
website, novavax.com.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
ir@novavax.com
240-268-2000
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024